Journal article
Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial
N Padayatchi, SS Abdool Karim, K Naidoo, A Grobler, G Friedland
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) | Published : 2014
Abstract
BACKGROUND: The therapeutic effects of antiretroviral treatment (ART) in patients with multidrug-resistant tuberculosis (MDR-TB) and human immunodeficiency virus (HIV) infection have not been established. OBJECTIVE: To assess therapeutic outcomes of integrating ART with treatment for MDR-TB. DESIGN: A subgroup of MDR-TB patients from a randomised controlled trial, the SAPiT (Starting Antiretroviral Therapy at Three Points in Tuberculosis) study, conducted in an out-patient clinic in Durban, South Africa, from 2008 to 2012. METHODS: Clinical outcomes at 18 months were compared in patients randomised to receive ART within 12 weeks of initiating standard first-line anti-tuberculosis treatment w..
View full abstractGrants
Awarded by US President's Emergency Plan for AIDS Relief (PEPFAR, Washington DC, USA)
Awarded by Comprehensive International Program of Research on AIDS (CIPRA)
Awarded by Fogarty International Center, NIH
Awarded by FOGARTY INTERNATIONAL CENTER
Awarded by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP)
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Funding Acknowledgements
This work was supported by the US President's Emergency Plan for AIDS Relief (PEPFAR, Washington DC, USA), which funded the care of all the participants in the trial (grant# 5U26PS001350); the Global Fund to Fight AIDS, Tuberculosis and Malaria (Geneva, Switzerland) funded the cost of the drugs used in the trial. The research infrastructure to conduct this trial, including data management, and laboratory and pharmacy cores were established through the Comprehensive International Program of Research on AIDS (CIPRA; grant # AI51794). CAPRISA was established as part of CIPRA from the US NIH. NP, AG and KN were supported by the Columbia University-Southern African Fogarty AIDS International Training and Research Program, funded by the Fogarty International Center, NIH (grant # D43TW00231).